The central innovation of wildDISCO lies in its unprecedented ability to render whole mouse bodies optically transparent while preserving cellular architecture and enabling deep antibody penetration. Researchers relied on standard immunoglobulin G (IgG) antibodies, a widely accessible reagent, to immunolabel the tissues, overcoming previous barriers related to uneven antibody distribution and limited permeability in dense organs. This opens new horizons for visualizing neuronal, vascular, immune, and lymphatic systems at resolutions that reveal the intricate cellular interplay within intact, intact mammalian anatomy.

A core technical hurdle surmounted by wildDISCO involves optimizing tissue permeabilization. To accomplish this, the research team harnessed cyclodextrin, a molecule celebrated for its cholesterol-extracting capabilities, as a potent enhancer of membrane permeability. By selectively removing cholesterol components from cellular membranes, cyclodextrin significantly improves tissue transparency and facilitates antibody diffusion deep into all organ compartments. This step is critical for consistent and complete immunostaining, which is essential for generating high-fidelity three-dimensional images.

The protocol starts with meticulous sample preparation, encompassing decolorization to eliminate endogenous pigments that obscure imaging signals and decalcification to address the inherent optical heterogeneity introduced by mineralized tissues such as bones. Careful calibration of these processes ensures that structural integrity is preserved while achieving the clarity required for downstream analyses. Such refinements are essential to produce artifact-free imaging data that can be faithfully registered and quantitated.

Following sample preparation, whole-body immunostaining involves immersing the mouse specimen in optimized antibody cocktails under conditions that promote uniform antibody penetration. This step, lasting several days, is carefully monitored and adjusted to achieve the desired labeling intensity and specificity across different tissue types. The multi-day immersion and incubation protocols reflect a significant advance from previous methods limited to superficial or thin-sliced samples.

Subsequent to immunolabeling, the biological specimen undergoes a clearing process that renders the tissue optically transparent, facilitating deep volumetric imaging without sectioning. This step leverages solvent-based clearing agents that preserve fluorescent signal and structural detail, enabling whole-body scans with high resolution. Together, these procedures form an integrated workflow that culminates in the generation of volumetric datasets capturing cellular distributions throughout the mouse.

Once cleared and stained, samples are imaged using state-of-the-art three-dimensional microscopy platforms, including light-sheet fluorescence microscopy, providing rapid, high-resolution volumetric data acquisition. This imaging modality reduces phototoxicity and bleaching while maintaining exquisite spatial detail, thereby preserving sample quality for repeated analyses. The resultant datasets offer unprecedented views into the spatial organization of cellular populations across the entire body.

Interrogating these comprehensive volumetric datasets necessitates advanced visualization technologies, and wildDISCO integrates virtual reality (VR) platforms to enable immersive exploration of the complex anatomical and molecular landscapes. This approach empowers researchers to navigate and annotate the three-dimensional cellular atlases intuitively, fostering discoveries that could be missed with traditional two-dimensional interpretation.

The protocol’s versatility allows for detailed studies of diverse biological systems, including neuronal circuitry, vascular expansion, lymphatic networks, and immune cell distributions, collectively enabling multi-system analyses from a single intact specimen. Such comprehensive mapping unlocks potential insights into system-wide interactions and pathophysiological states, which are often overlooked in reductionist studies focusing on isolated tissues.

Importantly, wildDISCO holds transformative potential for disease modeling. Researchers can implement this technique in various pathological contexts, such as tumor progression, metastatic dissemination, or microbiome-host interactions, to observe spatial-temporal dynamics at the cellular level throughout the whole body. This capability positions wildDISCO as a powerful tool to elucidate disease mechanisms and identify potential therapeutic targets.

While the methodology demands a 4-week commitment from start to finish, the streamlined workflow and reliance on standard immunohistochemistry reagents make wildDISCO broadly accessible to the scientific community. Successful application, however, may require initial technical training, especially for laboratories inexperienced in tissue clearing or sophisticated 3D imaging workflows. The authors anticipate that such skills will become widespread as the approach gains traction.

The anticipated impact of wildDISCO extends beyond basic research, with implications for translational science, regenerative medicine, and pharmacological testing. By enabling whole-organism, cellular-resolution mapping, this platform could accelerate drug development pipelines by providing holistic views of therapeutic effects and side effects, facilitating more precise interventions.

In essence, wildDISCO represents a paradigm shift in mammalian biology, establishing a robust, comprehensive methodology for generating whole-body cellular atlases, thus enabling unprecedented systems-level investigations into health and disease. As the scientific community embraces this innovation, the ability to visualize life’s complexity at an organismal scale promises to reshape our understanding of biology fundamentally.

The synergy of biochemical innovations such as cyclodextrin-enhanced clearing with cutting-edge imaging and computational visualization heralds a new era where comprehensive spatial maps become integral to routine biomedical explorations. WildDISCO’s cohesive integration of these technologies exemplifies the power of interdisciplinary collaboration in pushing the boundaries of what is technically achievable.

This protocol is poised to be a catalytic platform, bridging microscopic molecular insights with macroscopic organismal phenotypes, thereby facilitating discoveries that connect cellular dysfunction to systemic manifestations within the same biological specimen. Its adoption will likely spark a wave of innovative investigations into complex diseases that have, until now, remained refractory to full characterization.

In summary, the introduction of the wildDISCO methodology marks a monumental stride forward in whole-body biological imaging. By combining advanced tissue clearing, deep antibody penetration, and high-resolution 3D imaging, this protocol provides an indispensable toolkit for researchers aiming to unravel the intricate cellular orchestration governing mammalian life and disease progression.

Subject of Research: Whole-body immunolabeling and imaging for comprehensive mapping of cellular systems in mouse models.

Article Title: Whole-mouse immunolabeling at cellular resolution for comprehensive 3D atlases.

Article References:
Mai, H., Wang, Y., Zhu, Y. et al. Whole-mouse immunolabeling at cellular resolution for comprehensive 3D atlases. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01363-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-026-01363-9

Protein-protein interactions (PPIs) underpin nearly all cellular processes, from signal transduction and enzymatic catalysis to immune responses and structural integrity. Traditionally, studying these interactions or identifying molecules capable of modulating them has demanded laborious cell-based methods, which often impose constraints related to cellular viability, expression levels, and background noise. The CF2H platform bypasses these limitations by leveraging a cell-free context, thus opening avenues for rapid, high-throughput characterization of binder candidates without the hurdles imposed by cellular environments.

At its core, the CF2H methodology builds upon the classical two-hybrid principle, a widely employed technique to detect PPIs by reconstitution of a split transcription factor that triggers a reporter gene when two proteins interact. However, unlike conventional two-hybrid systems that rely on living cells—most commonly yeast or mammalian cell lines—CF2H operates with purified components in vitro. This transformation enables fine-tuned control over assay conditions, multimodal optimization, and direct coupling to downstream analytical techniques such as next-generation sequencing (NGS) or mass spectrometry.

The mechanics of CF2H involve synthesizing DNA templates encoding candidate binders and target proteins, followed by their transcription and translation within a cell-free expression system. These synthesized proteins can interact freely in solution, and when a binding event occurs between the candidate and the target protein, it triggers the reformation of a functional transcriptional activator capable of initiating a signal readout. This approach not only accelerates screening timelines but also circumvents issues such as cytotoxicity or poor expression that commonly hamper in vivo systems.

A noteworthy facet of the CF2H is its modular design, which supports rapid customization to interrogate a wide spectrum of protein targets and binding partners. The researchers demonstrated the platform’s versatility by successfully screening diverse binder libraries, ranging from small peptides to engineered scaffold proteins. This adaptability presents immense potential in antibody engineering, enzyme modulation, and synthetic biology, where tailored binders are indispensable tools for controlling biological activities.

Ensuring the robustness and sensitivity of CF2H was a critical challenge the team addressed through meticulous optimization of the cell-free reaction milieu. By fine-tuning key parameters such as ion concentrations, molecular crowding agents, and reaction temperature, they achieved a stable environment conducive to accurate binding interactions. Furthermore, integrating fluorescence-based reporters allowed real-time monitoring of binding events, thus facilitating high-throughput kinetic analyses.

Beyond proof-of-concept validation, the investigators harnessed high-throughput sequencing approaches coupled with CF2H to dissect large combinatorial libraries. This amalgamation allowed them to precisely quantify binding affinities and specificities at an unprecedented scale, revealing subtle nuances in protein interaction landscapes that traditional methods often miss. Such granularity is invaluable for designing superior binders with optimized therapeutic or diagnostic properties.

The rapid turnaround enabled by CF2H diminishes the time horizon from weeks or months to mere days, representing a transformative shift in binder discovery pipelines. This acceleration is paramount in contexts like emerging infectious disease outbreaks or personalized medicine, where swift development of modulators targeting novel or patient-specific proteins becomes essential.

In addition to methodological innovation, the CF2H platform promotes sustainability and cost-efficiency. Cell-free systems are inherently less resource-intensive, negating the need for cell culture infrastructure and reducing reagent consumption. This economic advantage dovetails with the growing demand for scalable, accessible technologies in molecular screening, particularly in resource-limited settings.

The platform’s design also incorporates compatibility with automation technologies, enabling integration with robotic liquid handling systems for fully automated screening campaigns. This scalability allows researchers to pursue expansive binder discovery projects while maintaining reproducibility and minimizing human intervention errors, further enhancing throughput and data quality.

Importantly, the CF2H system can be adapted for multiplexed screening, where multiple target proteins are simultaneously interrogated with binder libraries in a single reaction setup. Such multiplexing enables comparative analyses of binding affinities across diverse targets, informing prioritization strategies for therapeutic development and facilitating polypharmacology explorations.

Looking forward, the CF2H platform promises to catalyze innovations in drug discovery paradigms by bridging the gap between initial binder identification and functional characterization. Coupling CF2H with downstream assays such as cellular phenotyping or structural elucidation could streamline the transition from molecular hits to viable drug candidates, considerably expediting the overall pipeline.

The implications extend beyond pharmaceuticals; understanding and manipulating PPIs has key applications in synthetic biology, environmental biosensing, and biomaterials engineering. The CF2H technology thus stands as a versatile and powerful tool with the capacity to impact multiple domains where protein interactions are foundational.

While the CF2H platform presents a major leap, challenges remain in expanding the dynamic range of detectable binding affinities and in further refining specificity discrimination, particularly within highly complex biological mixtures. Nonetheless, the foundational work by Capin, Mayonove, DeVisch, and their associates offers a robust framework to tackle these hurdles through iterative improvements and community-driven innovation.

The unveiling of CF2H epitomizes the convergence of molecular biology, bioengineering, and computational analytics to redefine how researchers approach the intricate world of protein interactions. By enabling rapid, accurate, and flexible binder screening outside the confines of living cells, this technology lays the groundwork for accelerated discoveries that could revolutionize healthcare and biotechnology sectors.

As the molecular life sciences community begins to embrace and validate CF2H, its contribution is poised to become a cornerstone in the quest for novel therapeutics and biological tools. The ongoing evolution of cell-free synthetic biology approaches, exemplified by CF2H, underscores a future where biotechnology workflows become more modular, scalable, and responsive to emerging scientific challenges.

Subject of Research:
Development and application of a cell-free two-hybrid platform for rapid protein binder screening.

Article Title:
CF2H: a cell-free two-hybrid platform for rapid protein binder screening.

Article References:
Capin, J., Mayonove, P., DeVisch, A. et al. CF2H: a cell-free two-hybrid platform for rapid protein binder screening. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69741-1

Image Credits:
AI Generated

At the heart of this initiative lies a profound shift in our understanding of cellular biology. Contrary to earlier beliefs of uniformity within cell populations, researchers now recognize that blood and tissue samples harbor a complex mosaic of distinct cellular subtypes, each with unique molecular signatures. Professor Kathrin Schumann, an immunologist at the University of Konstanz, highlights the clinical ramifications of this heterogeneity, noting its critical importance in deciphering complex diseases and tailoring personalized therapeutic strategies. The ability to characterize cells individually allows scientists to discern subtle molecular variations that drive disease progression, thereby forging paths toward bespoke medicine.

The scientific capabilities of the Single Cell Centre revolve around three major instruments designed for comprehensive cellular interrogation. First, a high-speed cell sorter will enable the isolation of individual cells from heterogeneous populations, facilitating focused downstream analyses. Complementing this, a high-resolution mass spectrometer will provide detailed molecular profiling by quantifying proteins and metabolites at an unparalleled scale. Lastly, an advanced spectral analyzer will dissect cellular constituents through sophisticated light-based interrogation techniques, offering yet another dimension of insight. Together, these technologies constitute a powerful platform for unraveling cellular complexity previously inaccessible in the Lake Constance region and beyond.

The Centre’s ambitions extend beyond mere instrumentation. It embodies a training ground where emerging scientists will gain hands-on experience with single-cell analytical methodologies, bridging the gap between theoretical knowledge and practical expertise. This emphasis on education ensures a pipeline of skilled researchers adept at leveraging these sophisticated technologies, fostering a new generation capable of driving innovation forward in the biomedical sciences.

Professors Florian Stengel and Kathrin Schumann, alongside Dr. Annette Sommershof, spearhead the scientific coordination of the Centre. Their leadership integrates diverse expertise areas, from biochemistry to immunology, allowing the Centre to function as a multidisciplinary hub that advances fundamental and applied research. This collaborative ethos enhances the university’s Molecular Principles of Life research focus, amplifying the impact of collective scientific endeavors while cultivating partnerships with regional healthcare and industry stakeholders.

The infrastructural advancement heralded by the Single Cell Centre aligns strategically with the university’s participation in pivotal collaborative networks. Notably, it interfaces seamlessly with the transregional Collaborative Research Centre 353, dedicated to elucidating cellular decision-making processes during cell death, and the newly formed Collaborative Research Centre 1756, which investigates chemical and biological responses of cells under variable environmental stimuli. These collaborations amplify the Centre’s research scope, facilitating intricate studies on cellular behavior that underpin health and disease.

Beyond human biology, the Centre will extend its analytical scope to plant and animal cells, broadening the scientific horizon. This inclusivity reinforces the Centre’s standing as a versatile research institution, capable of addressing questions across a spectrum of biological disciplines. It supports diverse fields, from agricultural biotechnology to veterinary sciences, strengthening interdisciplinary research and fostering comprehensive biological insights.

Underpinning the realization of the Single Cell Centre is a significant investment from the Ministry of Science, Research and the Arts Baden-Württemberg, backed by the European Regional Development Fund with a budget of approximately 1.8 million euros. This funding underscores the regional and European commitment to elevating scientific infrastructure, with the anticipation that the Centre will catalyze breakthroughs in diagnostics and therapeutics that benefit society at large.

Core facilities like the Single Cell Centre embody a modern research paradigm where sophisticated instrumentation and methodological expertise are centralized, optimizing resource utilization and fostering collaborative innovation. Such platforms provide equitable access to high-end equipment and specialized knowledge not only to university members but also to external entities including healthcare providers and biotech enterprises, facilitating the translation of scientific discoveries into real-world applications.

The advent of single-cell analytics permits a granular understanding of how individual cells within a complex mixture respond to genetic alterations and environmental cues. This capability is transformative for personalized medicine, where treatments can be refined based on the molecular profile of single cells extracted from patient samples. Detecting minute protein changes and delineating cellular reaction pathways enables precision in identifying therapeutic targets and predicting treatment outcomes.

Furthermore, the single-cell approach augments diagnostics by providing the resolution necessary to detect rare cell populations or early molecular changes indicative of disease onset. This level of detail can revolutionize early detection of cancers, autoimmune disorders, and infectious diseases, thereby enhancing patient prognosis through timely intervention.

The establishment of the Single Cell Centre marks a pivotal step in consolidating the Lake Constance region’s position as a leading node in life sciences innovation. By equipping researchers and clinicians with unparalleled tools and fostering an ecosystem of collaboration, the Centre epitomizes the convergence of technology, education, and translational research. Its impact promises to ripple beyond academic boundaries, shaping healthcare delivery and biotechnological innovation for years to come.

Subject of Research: Single-cell analysis of human, plant, and animal cells to elucidate molecular heterogeneity and cellular responses to biochemical and genetic changes.

Article Title: University of Konstanz Launches State-of-the-Art Single Cell Centre to Revolutionize Biomedical Research

News Publication Date: Not specified.

Web References: Not specified.

References: Not specified.

Keywords: Cell biology, single-cell analysis, molecular heterogeneity, personalized medicine, cell sorting, mass spectrometry, biomedical diagnostics, biotechnology, immunology.

Dr. Charney’s research contributions have been pivotal in advancing our understanding of complex psychiatric disorders. As a neurobiologist specializing in the molecular bases of anxiety, fear, depression, and resilience, his work has yielded groundbreaking insights that have directly informed the development of novel therapeutic interventions. Notably, Dr. Charney was recognized as one of the 2025 TIME 100 Health Most Influential People in Health, a testament to his innovative approach and success in creating breakthrough treatments for depression. His research into the neurochemical pathways involved in mood regulation has helped usher in new pharmacological agents that offer hope to millions suffering from mental health conditions.

Under Dr. Charney’s visionary leadership, the Icahn School of Medicine embarked on a profound journey of expansion and scientific discovery. He actively cultivated a multidisciplinary environment by recruiting top-tier faculty across various fields such as biomedical sciences, computational biology, and information technology. This convergence of disciplines fostered an ecosystem of scientific risk-taking and resource sharing that challenged conventional boundaries within academic medicine. The school’s commitment to interdisciplinary collaboration led to the establishment of over two dozen research institutes dedicated to cutting-edge investigations in cancer, cardiovascular diseases, gastrointestinal disorders, and psychiatric illnesses, highlighting the school’s broad impact in multiple medical domains.

A defining hallmark of Dr. Charney’s tenure was the dramatic increase in funding from the National Institutes of Health (NIH), which soared to an unprecedented $500 million annually by 2024. This influx situates the Icahn School of Medicine at Mount Sinai as the 11th highest recipient of NIH funding among all U.S. medical schools and places it in the 99th percentile for research funding among private institutions. This financial support has empowered the school to advance its research infrastructure, recruit leading scientists, and train the next generation of medical innovators. Moreover, the expansion of the graduate medical education program under Dr. Charney’s leadership created the largest residency and clinical fellowship cohort in the nation, now exceeding 2,600 trainees.

Dr. Charney also forged strategic partnerships with technological and academic powerhouses such as the Hasso Plattner Institute, Rensselaer Polytechnic Institute, and the State University of New York at Stony Brook. These collaborations have been instrumental in developing digital health tools that advance precision medicine—a rapidly emerging field that leverages data analytics, machine learning, and personalized biological insights to optimize patient care. One historic advancement co-invented by Dr. Charney is ketamine, an FDA-approved rapid-acting antidepressant marketed as SPRAVATO™. Ketamine’s novel mechanism of action has revolutionized treatment paradigms for resistant depression, offering patients fast and effective relief where traditional antidepressants often fail.

In addition to pharmacological innovations, Dr. Charney is a pioneer in the digital therapeutics space, having co-developed Rejoyn, the first FDA-approved prescription digital therapeutic for major depressive disorder (MDD). This technology employs computer-guided behavioral therapy and data-driven patient engagement strategies that complement traditional medical treatments. Such digital interventions epitomize the future of mental health care, blending psychological science with software engineering to expand accessibility and efficacy. Dr. Charney’s dual achievement in both chemical and digital therapeutics exemplifies his comprehensive and forward-thinking approach to mental health research and treatment.

His scientific excellence has been recognized through numerous prestigious awards, cementing his status as a leader in psychiatric research. Dr. Charney was inducted into the National Academy of Medicine in 2000, a distinction reserved for individuals who have made profound contributions to medical science. His accolades include the Colvin Prize for Outstanding Achievement in Mood Disorder Research awarded in 2019 and the Rhoda & Bernard Sarnat International Prize in Mental Health from the National Academy of Medicine in 2023. These honors highlight his sustained commitment to understanding and addressing the biological underpinnings of mental illness.

The Mount Sinai Health System leadership has lauded Dr. Charney’s transformational impact on the school and health system. Brendan G. Carr, MD, and Kenneth L. Davis, MD, praised his ability to assemble a world-class team and secure the necessary resources that will sustain the school’s trajectory of excellence. They emphasized his unique leadership qualities that blend innovative thinking with steadfast dedication. Similarly, Kenneth L. Davis reflected on Dr. Charney’s “outside-the-box” leadership style, which defied traditional constraints and forged a culture strong enough to elevate the Icahn School of Medicine into a premier institution for biomedical education and research.

Echoing this sentiment, Richard A. Friedman and James S. Tisch, Co-Chairs of the Mount Sinai Health System Boards of Trustees, referred to Dr. Charney as a visionary transformative leader who successfully implanted an entrepreneurial spirit within the school. By fostering an environment conducive to innovation and risk-taking, Dr. Charney created a dynamic academic culture that continues to push the boundaries of biomedical research and patient care. His strategic direction is seen as a cornerstone of the institution’s success and future potential.

In the wake of this leadership transition, Eric J. Nestler, MD, PhD, has been appointed as Interim Dean of the Icahn School of Medicine. Dr. Nestler is a distinguished molecular neuroscientist known for his work on the mechanisms underlying addiction and depression. He has served as Dean for Academic Affairs since 2016 and as Chief Scientific Officer of the Mount Sinai Health System, with a prolific publication record of over 750 papers and five books. His election to the National Academy of Sciences—the highest honor for original scientific research—underscores his stature in the biomedical community and promises continuity in the school’s scientific mission.

Mount Sinai Health System itself stands as a pillar of comprehensive care and biomedical innovation in the New York metropolitan area. Employing 48,000 staff across seven hospitals, over 400 outpatient practices, and more than 600 research and clinical laboratories, it is among the largest academic medical systems in the region. The Health System’s integrated model combines cutting-edge scientific research, education, and clinical care to address complex health challenges using novel technologies including artificial intelligence and informatics. Its hospitals routinely receive accolades from Newsweek and U.S. News & World Report, reflecting their excellence in healthcare delivery.

The Icahn School of Medicine’s ever-expanding research footprint and educational programs have played an essential role within this ecosystem. Taking advantage of state-of-the-art facilities and a comprehensive network of healthcare providers, faculty and students are uniquely positioned to translate scientific discoveries into tangible health improvements. The synergy between research and clinical enterprises fuels innovations that continue to broaden treatment options for a wide spectrum of diseases, from cancer and heart disease to psychiatric and gastrointestinal disorders.

Looking ahead, the Icahn School of Medicine at Mount Sinai is poised to build on the foundation laid by Dr. Charney’s leadership. The school’s emphasis on cross-disciplinary collaboration, augmented by strategic partnerships and cutting-edge digital health innovations, positions it as a global leader ready to tackle the evolving challenges of medicine. As Dr. Nestler steps into his interim role, the institution’s vibrant culture of research excellence and education stands insured, ensuring that the next generation of physicians and scientists will carry the torch forward.

Subject of Research: Neurobiology of mood disorders, mechanisms of depression and anxiety, development of novel pharmacological and digital therapeutics.

Article Title: Not explicitly provided in the source content.

News Publication Date: May 13, 2025

Web References:
https://time.com/collections/time100-health-2025/7279649/dennis-charney/

Keywords: Health and medicine, neurobiology, depression, anxiety, resilience, ketamine, SPRAVATO™, digital therapeutics, Rejoyn, biomedical innovation, academic medicine, precision medicine.